Granted Patent
B2
US 12,679,888 · App. 18/436,802 · Granted Jul 14, 2026
IL-18 binding protein (IL-18BP) and antibodies for treating inflammatory diseases
Assignee:
AB2 BIO SA
C07K16/244A61K38/1709G01N33/6869A61K2039/505A61K2039/545C07K2317/30C07K2317/76C07K2317/92G01N2333/54
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides means and methods for treating Interleukin 18 (IL-18)-associated diseases and disorders. In particular, the present invention discloses antibodies specific for free IL-18 and IL-18 Binding Protein (IL-18BP) for use in such treatments and for the diagnosis of the diseases and disorders.
Claims (19)
1 . A method for the treatment of an IL-18 associated autoinflammatory disease or disorder and/or symptoms associated with said disease or disorder in a subject, said method comprising administering to said subject an IL-18 inhibitor, wherein the IL-18 inhibitor is an IL-18 binding protein (IL-18BP) or an active fragment thereof, wherein the IL-18BP or the active fragment thereof comprises N-terminal and/or C-terminal deletion variants of IL-18BP, which are present in an amount of less than 30%, wherein the IL-18 associated autoinflammatory disease or disorder is selected from juvenile idiopathic arthritis (JIA), systemic juvenile idiopathic arthritis (sJIA), systemic onset juvenile idiopathic arthritis (SoJIA), SoJIA with macrophage activation syndrome (SoJIA-MAS), or interstitial lung disease (ILD).
2 . The method of claim 1 , wherein the body fluids of said subject have been quantified to have abnormal levels of free IL-18, which exceed the level of free IL-18 in body fluids of a healthy control subject by 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, or more than 100%.
3 . The method of claim 2 , wherein the level of free IL-18 in the body fluids has been determined to be ≥5 μg/mL as compared to ≤4 μg/mL in the healthy control subject.
4 . The method of claim 1 , wherein the IL18-BP is human IL-18BP.
5 . The method of claim 4 , wherein said human IL-18BP is selected from isoforms a, b, c and d of human IL-18BP.
6 . The method of claim 1 , wherein said deletion variants comprise deletions of between 1 and 5 amino acid residues at the C-terminal end of the IL-18BP and/or between 1 and 30 amino acid residues at the N-terminal end of the IL-18BP.
7 . The method of claim 1 , wherein the IL-18 associated autoinflammatory disease or disorder is accompanied by high levels of IL-18 and free IL-18.
8 . The method of claim 1 , wherein the IL-18 BP or the active fragment thereof is administered to the subject in need thereof in one or multiple doses/day, in one or multiple doses/week or in one or multiple doses/month.
9 . The method of claim 1 , wherein the IL-18 BP or the active fragment thereof is administered in one dose per week, in two doses per week, three doses per week, or four doses per week.
10 . The method of claim 9 , wherein a single dose comprises between 0.5 mg and 600 mg IL-18BP.
11 . The method of claim 9 , wherein a single dose comprises between 0.5 mg of IL-18BP/kg body weight and 10 mg of IL-18BP/kg body weight.
12 . The method of claim 9 , wherein a single dose of between 0.5 mg of IL-18BP/kg body weight and 5 mg of IL-18BP/kg body weight is administered every 24 or 48 hours.
13 . The method of claim 9 , wherein a single dose of 2 mg of IL-18BP/kg body weight is administered every 48 hours.
14 . The method of claim 1 , wherein the IL-18 BP or the active fragment thereof is administered every 24 hours to 48 hours.
15 . The method of claim 1 , wherein the IL-18 inhibitor is administered to the subject subcutaneously.
16 . The method of claim 1 , wherein the subject is a human.
17 . The method of claim 1 , wherein the IL-18 associated autoinflammatory disease or disorder is induced by viral infection.
18 . The method of claim 1 , further comprising administering to the subject a glucocorticoid.
19 . The method of claim 18 , wherein the glucocorticoid is dexamethasone.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 8, 2024
From: DEL VAL, GREG; SCHIFFRIN, EDUARDO
To: AB2 BIO SA
Reel/Frame 066420/0647 →
Priority Claims (3)
EP 15157742
· Mar 5, 2015
· regional
EP 15158781
· Mar 12, 2015
· regional
EP 15186626
· Sep 24, 2015
· regional
Continuity (4)
References Cited (153)
US 6605280B1
· Novick et al.
· 2003
[cited by applicant]
US 7696154B2
· Novick et al.
· 2010
[cited by applicant]
US 7824907B2
· Chatellard et al.
· 2010
[cited by applicant]
US 9255144B2
· Dobson et al.
· 2016
[cited by applicant]
US 9376489B2
· Bardoff et al.
· 2016
[cited by applicant]
US 20020098185A1
· Sims et al.
· 2002
[cited by applicant]
US 20030008822A1
· Dinarello et al.
· 2003
[cited by applicant]
US 20040076628A1
· Chvatchko et al.
· 2004
[cited by applicant]
US 20040234523A1
· Dinarello et al.
· 2004
[cited by applicant]
US 20050100965A1
· Ghayur et al.
· 2005
[cited by applicant]
US 20070264237A1
· Rubinstein et al.
· 2007
[cited by applicant]
US 20130004416A1
· Wu et al.
· 2013
[cited by applicant]
US 20130072441A1
· Hoshino et al.
· 2013
[cited by applicant]
AU 2011224023C1
· 2013
[cited by applicant]
CL 200100316
· 2001
[cited by applicant]
CL 200701478
· 2007
[cited by applicant]
EP 2161032A2
· 2010
[cited by applicant]
JP 2008541748A
· 2008
[cited by applicant]
JP 2009102354A
· 2009
[cited by applicant]
JP 2014508511A
· 2014
[cited by applicant]
WO 1999009063A1
· 1999
[cited by applicant]
WO 2001058956A2
· 2001
[cited by applicant]
WO 2001062285A1
· 2001
[cited by applicant]
WO 0158956A3
· 2002
[cited by applicant]
WO 200232374A2
· 2002
[cited by applicant]
WO 2002060479A1
· 2002
[cited by applicant]
WO 2002096456A1
· 2002
[cited by applicant]
WO 2004101617A1
· 2004
[cited by applicant]
WO 2005087249A1
· 2005
[cited by applicant]
WO 2006128908A1
· 2006
[cited by applicant]
WO 2007030949A2
· 2007
[cited by applicant]
WO 2012085015A1
· 2012
[cited by applicant]
WO 2014037899A2
· 2014
[cited by applicant]
WO 2015032932A1
· 2015
[cited by applicant]
WO 2016139297A1
· 2016
[cited by applicant]
Krumm et al., “A Unique Bivalent Binding and Inhibition Mechanism by the Yatapoxvirus Interleukin 18 Binding Protein,” PLOS Pathogens, vol. 8, Issue 8, e1002876: pp. 1-15 (2012).
[cited by applicant]
Thompson et al., “Free interleukin (IL)-18 levels, and the impact of IL18 and IL18BP genetic variation, in CHD patients and healthy men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, No. 12, pp. 2743-274…
[cited by applicant]
Zeng, Hua-Song et al. “Macrophage activation syndrome in 13 children with systemic-onset juvenile idiopathic arthritis,” World Journal of Pediatrics, vol. 4, No. 2 (May 2008) pp. 97-101.
[cited by applicant]
Daley, “Pulmonary arterial remodeling induced by a Th2 immune response”, J Exp Med, vol. 205, 2008, 361-372.
[cited by applicant]
Dinarello, et al. “Interleukin 1 and IL-18 Binding Protein,” Frontiers Immunology, vol. 4 (Jan. 1, 2013) pp. 1-10.
[cited by applicant]
Elias, et al., “Mechanistic heterogeneity in chronic obstructive pulmonary disease: insights from transgenic mice”, Proc Am Thorac Soc, 2006, 494-498.
[cited by applicant]
Eltom, et al., “P2X7 Receptor and Caspase-1 Activation Are Central to Airway Inflammation Observed after Exposure to Tobacco Smoke”, PLoS ONE, vol. 6, No. 9, 2011, e24097.
[cited by applicant]
Hackett, et al., “Clara cell secretory protein gene expression in bronchiolar epithelium”, Am J Physiol, vol. 262, 1992, L399-L404.
[cited by applicant]
Halbower, et al., “Agarose infiltration improves morphology of cryostat sections of lung”, Lab Invest, vol. 71, 1994, 149-153.
[cited by applicant]
Hautamaki, et al., “Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice”, Science, vol. 277, 1997, 2002-2004.
[cited by applicant]
Hoshino, et al., “IL-18-transgenic mice: in vivo evidence of a broad role for IL-18 in modulating immune function”, J Immunol, 2001, 7014-7018.
[cited by applicant]
Hoshino, et al., “Pulmonary inflammation and emphysema: role of the cytokines IL-18 and IL-13”, Am J Respir Crit Care Med, 2007, 49-62.
[cited by applicant]
Hou, et al., “Humanization of an anti-CD34 monoclonal antibody by complementarity-determining region grafting based on computer-assisted molecular modeling”, J Biochem, vol. 144, No. 1, Jul. 2008, 115-120.
[cited by applicant]
Imaoka, et al., “Interleukin-18 production and pulmonary function in COPD”, Eur Respir J, 2008, 287-297.
[cited by applicant]
Jaatinen, et al., “Isolation of mononuclear cells from human cord blood by Ficoll-Paque density gradient”, Curr Protoc Stem Cell Biol, Chapter 2:Unit 2A.1, 2007.
[cited by applicant]
Kang, et al., “Cigarette smoke selectively enhances viral PAMP- and virus-induced pulmonary innate immune and remodeling responses in mice”, J Clin Invest, vol. 118, 2008, 2771-2784.
[cited by applicant]
Kang, et al., “IL-18 induces emphysema and airway and vascular remodeling via IFNy, IL-17A, and IL-13”, Am J Respir Crit Care Med, 2012, 1205-1217.
[cited by applicant]
Kang, et al., “IL-18 is induced and IL-18 receptor alpha plays a critical role in the pathogenesis of cigarette smoke-induced pulmonary emphysema and inflammation”, J Immunol, 2007, 1948-1959.
[cited by applicant]
Kashmiri, et al., “SDR grafting—a new approach to antibody humanization”, Methods, vol. 36, No. 1, May 2005, 25-34.
[cited by applicant]
Kawashima, et al., “Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease”, Arthritis Rheum, vol. 44, No. 3, 2001, 550-560.
[cited by applicant]
Kim, et al., “Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18”, Proc Natl Acad Sci USA, vol. 97, No. 3, 2000, 1190-1195.
[cited by applicant]
Kratzer, et al., “Role of IL-18 in second hand smoke-induced emphysema”, Am J Respir Cell Mol Biol, vol. 48, No. 6, 2013, 725-32.
[cited by applicant]
Lee, et al., “Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis”, J Exp Med, vol. 206, 2009, 1149-1166.
[cited by applicant]
Lee, et al., “Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung”, Nat Med 2004, vol. 10, 2004, 1095-1103.
[cited by applicant]
Liu, et al., “Requirement for tumor necrosis factor-receptor 2 in alveolar chemokine expression depends upon the form of the ligand”, Am J Respir Cell Mol Biol, vol. 33, 2005, 463-469.
[cited by applicant]
Lochner et al. “Anti-Interleukin 18 Therapy in Murine Models of Inflammatory Bowel Disease,” Pathobiology, vol. 70, issue 3 (Jan. 1, 2002) pp. 164-169.
[cited by applicant]
Lochner et al. “Generation of Neutralizing Mouse Anti-Mouse IL-18 Antibody for Inhibition of Inflammatory Responses in Vivo,” Journal of Immunologic Methods (Jan. 1, 2002) pp. 149-157.
[cited by applicant]
Londhe, et al., “A Subset of Epithelial Cells with CCSP Promoter Activity Participates in Alveolar Development”, Am J Respir Cell Mol Biol, vol. 44, 2011, 804-812.
[cited by applicant]
Londhe, et al., “Systemic inflammatory profile and response to anti-tumor necrosis factor therapy in chronic obstructive pulmonary disease”, Respir Res, 2012, 12.
[cited by applicant]
Loza, et al., “Systemic Inflammatory Profile and Response to Anti-Tumor Necrosis Factor Therapy in Chronic Obstructive Pulmonary Disease”, Respir Res, 2012, 12.
[cited by applicant]
Ma, et al., “Role Of CCR5 In IFN-y-Induced And Cigarette Smoke-Induced Emphysema”, J Clin Invest, vol. 115, 2005, 3460-3472.
[cited by applicant]
Nakajima, et al., “The Master Regulator Driving Destructive and Remodeling Processes in the Lungs of Patients with Chronic Obstructive Pulmonary Disease?”, Am J Respir Crit Care Med, 2012, 1137-1138.
[cited by applicant]
Novick, et al., “A Novel IL-18BP Elisa Shows Elevated Serum IL-18BP In Sepsis and Extensive Decrease Of Free IL-18”, Cytokine, vol. 14, 2001, 334-342.
[cited by applicant]
Park, et al., “Elevated interleukin-18 levels correlated with disease activity in systemic lupus erythematosus”, Clin Rheumatol, vol. 23, 2004, 225-229.
[cited by applicant]
Petersen, et al., “Elevated Levels of IL-18 in Plasma and Skeletal Muscle in Chronic Obstructive Pulmonary Disease”, Lung, 2007, 161-171.
[cited by applicant]
Queen, et al., “A Humanized Antibody that Binds to the Interleukin 2 Receptor,” Proc Natl Acad Sci U.S.A., vol. 86, No. 24, Dec. 1989, 10029-10033.
[cited by applicant]
Rastrick, et al., “Cigarette Smoke Induced Airway Inflammation Is Independent of NF-KB Signalling”, PLoS ONE, vol. 8, No. 1, 2013, e54128.
[cited by applicant]
Ray, et al., “Regulated Overexpression of Interleukin 11 In the Lung: Use to Dissociate Development-Dependent And -Independent Phenotypes”, J Clin Invest, vol. 100, 1997, 2501-2511.
[cited by applicant]
Reed, et al., “A Simple Method of Estimating 50% Endpoints”, Am J Hyg, vol. 27, 1938, 493-497.
[cited by applicant]
Riechmann, et al., “Reshaping Human Antibodies for Therapy”, Nature, vol. 332, No. 6162, 1988, 332-323.
[cited by applicant]
International Search Report for PCT/EP2014/05901, dated Jan. 8, 2015, 8 pages.
[cited by applicant]
Rovina, et al., “Interleukin-18 in Induced Sputum: Association with Lung Function in Chronic Obstructive Pulmonary Disease”, Respiratory Medicine, 2009, 1056-1062.
[cited by applicant]
Shapiro, et al., “Transgenic and Gene-Targeted Mice as Models for Chronic Obstructive Pulmonary Disease”, Eur J Respir, 2007, 375-378.
[cited by applicant]
Sivakumar, et al., “Interleukin 18 Is a Primary Mediator of the Inflammation Associated with Dextran Sulphate Sodium Induced Colitis: Blocking Interleukin 18 Attenuates Intestinal Damage”, Gut, vol. 50, No. 6, 2002, 812…
[cited by applicant]
Taniguchi, et al., “Characterization of Anti-Human Interleukin-18 (IL-18)/Interferon-Gamma-Inducing Factor (IGIF) Monoclonal Antibodies and Their Application in the Measurement Of Human IL-18 by ELISA”, J Immunol Method…
[cited by applicant]
Wang, et al., “Increased Expression of Interleukin-18 and its Receptor in Peripheral Blood of Patients with Chronic Obstructive Pulmonary Disease”, COPD, vol. 9, No. 4, 2012, 375-381.
[cited by applicant]
Wang, et al., “Interferon γ Induction of Pulmonary Emphysema in the Adult Murine Lung”, J Exp Med, vol. 192, 2000, 1587-1600.
[cited by applicant]
Efthimiou, P et al. “Diagnosis and management of adult onset Still's disease,” Annals of the Rheumatic Diseases, vol. 65, issue 5 (Oct. 11, 2005) pp. 654-572.
[cited by applicant]
Bork et al., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle,” Genome Research, vol. 10, pp. 398-400 (2000).
[cited by applicant]
Doerks et al., “Protein Annotation: Detective Work for Function Prediction,” Trends in Genetics, vol. 14, No. 6, pp. 240-250 (1998).
[cited by applicant]
Skolnick et al., “From genes to protein structure and function: novel applications of computational approaches in the genomic area,” Trends in Biotechnology, vol. 18, No. 1, pp. 34-39 (2000).
[cited by applicant]
Wells et al., “Additivity of Mutational Effects in Proteins,” Biochemistry, vol. 29, No. 37, pp. 8509-8517, (1990).
[cited by applicant]
Jordan et al., “Role of IL-18 in Acute Lung Inflammation,” The Journal of Immunology, vol. 167, pp. 7060-7068 (2001).
[cited by applicant]
Dinarello, C. A. “Novel targets for interleukin 18 binding protein”, Annals of the Rheumatic Diseases, vol. 60, suppl 3, (2001) pp. iii 18-iii24.
[cited by applicant]
Shigemura, Tomonari et al., “Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome,” Pediatric Rheumatology, vol. 9,…
[cited by applicant]
Office Action issued by the Federal Service for Intellectual Property (ROSPATENT), Ministry of Economic Development of the Russian Federation for counterpart Application No. RU2017134857 on Nov. 24, 2020.
[cited by applicant]
Communication pursuant to Article 94(3) EPC, issued by the European Patent Office on May 25, 2020 for counterpart application No. 16707773.4, pp. 1-6.
[cited by applicant]
Examination Report, issued by The Intellectual Property Office of India on Feb. 12, 2019 for counterpart application No. 201647012010, pp. 1-7.
[cited by applicant]
Hornbeck, Peter et al., “Enzyme-Linked Immunosorbent Assays (ELISA),” Current Protocols in Molecular Biology, chapter 2, unit 2.1 (2001) pp. 11.2.1-11.2.22.
[cited by applicant]
Tokuriki, Nobuhiko et al. “Stability effects of mutations and protein evolvability,” Current Opinion in Structural Biology, vol. 19 (Sep. 16, 2009) pp. 596-604.
[cited by applicant]
Bhattacharya, Roshni et al. “Impact of genetic variation on three dimensional structure and function of proteins,” PLoS ONE, vol. 12, issue 3 (Mar. 15, 2017) pp. 1-22.
[cited by applicant]
Guo, Haiwei H. et al. “Protein tolerance to random amino acid change,” Proceedings of the National Academy of Sciences of the United States of America (PNAS) vol. 101, No. 25 (Jun. 22, 2004) pp. 9205-9210.
[cited by applicant]
Fenton, Aron W. et al. “Rheostat positions: A new classification of protein positions relevant to pharmacogenomics,” Medicinal Chemistry Research, vol. 29 (2020) pp. 1133-1146.
[cited by applicant]
Priori, Roberta, et al. “Markedly increased IL-18 liver expression in adult-onset Still's disease-related hepatitis,” Rheumatology, vol. 50, issue 4 (Apr. 2011) pp. 776-780.
[cited by applicant]
Peterson, A. M. W. et al., “Elevated Lung of IL-18 in Plasma and Skeletal Muscle in Chronic Obstructive Pulmonary Disease,” Lung, vol. 185 (2007) pp. 161-171.
[cited by applicant]
Novick, Daniela et al.“High circulating levels of free interleukin-18 in patients with active SLE in the presence of elevated levels of interleukin-18 binding protein,” Journal of Autoimmunity, vol. 34, issue 2 (Mar. 20…
[cited by applicant]
Dinarello, Charles A. “Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process,” The American Journal of Clinical Nutrition, vol. 83, issue 2 (Feb. 1, 2006) pp. 447S-455S.
[cited by applicant]
Khoury, Maroun et al., “Efficient suppression of murine arthritis by combined anticytokine small interfering RNA lipoplexes,” Arthritis & Rheumatism, vol. 58, No. 8 (Aug. 2008) pp. 2356-2367.
[cited by applicant]
Krumm, Brian et al., “Identification of small molecule inhibitors of Interleukin-18,” Scientific Reports, vol. 7, issue 483 (Mar. 28, 2017) pp. 1-8.
[cited by applicant]
Gabay, Cem et al., “Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease,” Annals of the Rheumatic Diseases, vol. 77 (201…
[cited by applicant]
Kiltz, Uta et al., “Prolonged treatment with Tadeking alfa in adult-onset Still's disease,” Annals of the Rheumatic Diseases, vol. 79, No. 1 (Jan. 2020) pp. 1-2.
[cited by applicant]
Office Action issued by the Japanese Patent Office (JPO) for corresponding JP Patent Application No. 2016-539564 on Jul. 25, 2019.
[cited by applicant]
Mariuzza, R. A. et al., “The Structural Basis of Antigen-Antibody Recognition,” Annual Review of Biophysics and Biophysical Chemistry, vol. 16 (1987) pp. 139-159.
[cited by applicant]
Novick, Daniela et al. “Interleukin-18 Binding Protein [
[cited by applicant]
Novick, Daniela et al. “Interleukin-18 Binding Protein: A Novel Modulator of the Th1 Cytokine Response,” Immunity, vol. 10, issue 1 (Jan. 199) pp. 127-138.
[cited by applicant]
Esteban, David J. et al., “Identification of residues in an orthopoxvirus interleukin-18 binding protein involved in ligand binding and species specificity,” Virology, vol. 323, issue 2 (Jun. 1, 2004) pp. 197-207.
[cited by applicant]
Kim, Soo-Hyun et al., “Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18,” Proceedings of the National Academy of Sciences of the United States of America (PNAS), …
[cited by applicant]
Krumm, Brian et al., “Structural basis for antagonism of human interleukin 18 by poxvirus interleukin 18-binding protein,” Proceedings of the National Academy of Sciences of the United States of America (PNAS), vol. 105…
[cited by applicant]
Xiang, Yan et al., “Determination of the Functional Epitopes of Human Interleukin-18-binding Protein by Site-Directed Mutagenesis*,” Journal of Biological Chemistry, vol. 276, No. 20 (May 18, 2001) pp. 17380-17386.
[cited by applicant]
Office Action issued by the Japanese Patent Office (JPO) for corresponding JP Patent Application No. 2017-546603 dispatched Dec. 25, 2019.
[cited by applicant]
Yakushenko, E.V. et al., “Interleukin-18 and Its Role in the Immune Response,” Medical Immunology (Russia), vol. 7, No. 4 (2005) pp. 355-364.
[cited by applicant]
Wada, Taizo et al., “Sustained elevation of serum interleukin-18 and its association with hemophagocytic lymphohistiocytosis in XIAP deficiency,” Cytokine, vol. 65, issue 1 (Sep. 29, 2013) pp. 74-78.
[cited by applicant]
Canna, Scott et al., “An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome,” Nature Genetics, vol. 46, No. 10 (Oct. 2014) pp. 1140-1146.
[cited by applicant]
Migliorini, Paola et al., “Free circulating interleukin-18 is increased in Schnitzler syndrome: a new autoinflammatory disease?,” European Cytokine Network, vol. 20, issue. 3 (Sep. 2009) pp. 108-111.
[cited by applicant]
Mazodier, Karin et al., “Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome,” Blood, vol. 106, No. 10 (2005) pp. 3483-3489.
[cited by applicant]
International Search Report and Written Opinion issued by the European Patent Office for PCT/EP2016/054524 on Mar. 8, 2016.
[cited by applicant]
Office Action issued by the Republic of Columbia Superintendence of Industry and Trade for corresponding CO Patent Application No. NC2017/0008940 on Mar. 19, 2019.
[cited by applicant]
Wong, C. K. et al. “Elevation of plasma interleukin-18 concentration is correlated with disease activity in systemic lupus erythematosus,” Rheumatology (Oxford), vol. 39, issue 10 (Oct. 2000) pp. 1078-1081.
[cited by applicant]
Wright, Joanne L. et al. “Animal models of chronic obstructive pulmonary disease,” American Journal of Physiology-Lung Cellular and Molecular Physiology, vol. 295, issue 1 (Jul. 2008) pp. L1-L15.
[cited by applicant]
Zhang, Jianhong et al. “Isolation of lymphocytes and their innate immune characterizations from liver, intestine, lung and uterus,” Cellular & Molecular Immunology, vol. 2, No. 4 (Aug. 2005) pp. 271-280.
[cited by applicant]
Zheng, Tao et al. “Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase- and cathepsin-dependent emphysema,” Journal of Clinical Investigation, vol. 106, issue 9 (Nov. 1, 2000) pp. 1081-1093.
[cited by applicant]
Zheng, Tao et al. “Role of cathepsin S-dependent epithelial cell apoptosis in IFN-γ-induced alveolar remodeling and pulmonary emphysema,” Journal of Immunology, vol. 174, issue 12 (Jun. 15, 2005) pp. 8106-8115.
[cited by applicant]
Colombian Office Action for Colombian Patent Application No. 16-077.559, Jan. 2018, 12 pages.
[cited by applicant]
Japanese Office Action for Japanese Patent Application No. 2016-539564 (English-language translation provided), Mar. 1, 2018, pp. 1-13.
[cited by applicant]
Chilean Office Action for Chilean Patent Application No. 0506-2016 (English-language translation included), Aug. 9, 2017, 16.
[cited by applicant]
Argiriadi, Maria A. et al., “Unusual Water-Mediated Antigenic Recognition of the Proinflammatory Cytokine Interleukin-18,” Journal of Biological Chemistry, vol. 284,1 issue 36 (Sep. 2009) pp. 24478-24489.
[cited by applicant]
Azoulay, É et al., “Granulocyte colony-stimulating factor enhances alpha-naphthylthiourea-induced pulmonary hypertension,” Journal of Applied Physiology, vol. 94, issue 5 (May 2003) pp. 2027-2033.
[cited by applicant]
Baron, Rebecca M. et al., “Genetically manipulated mouse models of lung disease: potential and pitfalls,” American Journal of Physiology—Lung Cellular and Molecular Physiology, vol. 302, issue 6 (Mar. 2012) pp. L485-L49…
[cited by applicant]
Cao, Qizhen et al., “Multimodality Imaging of IL-18-Binding Protein-Fc Therapy for Experimental Lung Metastasis,” Clinical Cancer Research, vol. 14, issue 19 (Oct. 1, 2008) pp. 6137-6145.
[cited by applicant]
Chen, D. Y. et al., “Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease,” Annals of the Rheumatic Diseases, vol. 63, issue 10 (2004) p…
[cited by applicant]
Chen, et al., “Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease,” The Journal of Rheumatology, vol. 31, issue 11 (Nov. 1, 2004) pp. 2189-21…
[cited by applicant]
Colafrancesco, Serena et al., “IL-18 Serum Level in Adult Onset Still's Disease: A Marker of Disease Activity,” International Journal of Inflammation, vol. 2012, Article ID No. 156890 (2012) pp. 1-6.
[cited by applicant]
Cunningham, Robert E, “Tissue disaggregation,” Immunocytochemical Methods and Protocols (Methods in Molecular Biology), vol. 588 (Oct. 28, 2009) pp. 327-330.
[cited by applicant]